2cureX AB (SE:2CUREX)
:2CUREX
Top Page
2cureX AB
(2CUREX)
Select Model
Select Model
Rating:54Neutral
Price Target:
kr2.00
▲(270.37% Upside)
Action:ReiteratedDate:02/04/26
The score is held back primarily by weak financial performance (ongoing losses, minimal revenue, and negative free cash flow despite improvement in 2024). Technical indicators are comparatively stronger (positive momentum and price above key short/mid-term averages), while valuation is mixed due to a high dividend yield offset by a negative P/E.
Positive Factors
Debt-free balance sheet
Having no debt materially reduces fixed obligations and financial distress risk, giving management flexibility to fund operations via equity, partnerships, or grant funding. This durable balance-sheet strength supports continued R&D and commercialization efforts over the next several months.
Negative Factors
Near-zero revenue
Volatile and effectively negligible revenue (declines to near-zero) signals weak commercial traction and makes scaling the test platform uncertain. Without sustainable test volumes or contracted revenue, the business struggles to convert R&D into durable, predictable income.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Having no debt materially reduces fixed obligations and financial distress risk, giving management flexibility to fund operations via equity, partnerships, or grant funding. This durable balance-sheet strength supports continued R&D and commercialization efforts over the next several months.
Read all positive factors
2cureX AB (2CUREX) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr28.87M
Dividend Yield11.26%
Average Volume (3M)53.14K
Price to Earnings (P/E)―
Beta (1Y)1.69
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding25,102,917
10 Day Avg. Volume69,592
30 Day Avg. Volume53,143
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr240.00M
2cureX AB Business Overview & Revenue Model
Company Description
2cureX AB (publ) operates as a medtech company in Europe. Its principal product is IndiTreat, an IVD test, which helps to predict cancer patient's response and resistance to different drugs and select the appropriate treatment. The company is also...
How the Company Makes Money
2cureX’s business model is centered on monetizing its functional drug response testing platform through commercialization in clinical and research settings. Key revenue streams are intended to include: (1) fees for performing patient-specific drug...
2cureX AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
54
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.18M | 0.00 | 155.00K | 90.00K | 7.39M | 15.39M |
| Gross Profit | -12.53M | 0.00 | -9.27M | -9.02M | 7.04M | 15.01M |
| EBITDA | -28.18M | -4.13M | -35.14M | -29.46M | -22.13M | -8.21M |
| Net Income | -24.65M | -4.13M | -32.52M | -29.77M | -18.94M | -7.32M |
Balance Sheet | ||||||
| Total Assets | 7.05M | 7.75M | 16.28M | 47.66M | 79.16M | 63.04M |
| Cash, Cash Equivalents and Short-Term Investments | 3.13M | 5.14M | 13.40M | 44.89M | 72.94M | 58.58M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 4.26M | 2.65M | 4.20M | 4.62M | 4.82M | 4.18M |
| Stockholders Equity | 2.79M | 5.10M | 12.08M | 43.03M | 74.34M | 58.86M |
Cash Flow | ||||||
| Free Cash Flow | -22.61M | -4.63M | -31.24M | -28.52M | -18.46M | -12.10M |
| Operating Cash Flow | -22.59M | -4.63M | -31.22M | -27.98M | -18.43M | -11.69M |
| Investing Cash Flow | -6.00K | 5.62M | -17.00K | -541.00K | -32.00K | -403.00K |
| Financing Cash Flow | 0.00 | 2.69M | 0.00 | 0.00 | 32.55M | 37.61M |
2cureX AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:2CUREX
2cureX AB
1.15
0.81
238.24%
DE:8LY
OncoZenge AB
0.51
-0.04
-6.65%
DE:5JD0
ExpreS2ion Biotech Holding AB
0.30
-1.67
-84.92%
DE:COJ0
CombiGene AB
0.16
>-0.01
-5.20%
DE:5JA1
Sprint Bioscience AB
0.17
0.12
250.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.